Cargando…

Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72)

AIMS: Frontotemporal dementias are neuropathologically characterised by frontotemporal lobar degeneration (FTLD). Intraneuronal inclusions of transactive response DNA‐binding protein 43 kDa (TDP‐43) are the defining pathological hallmark of approximately half of the FTLD cases, being referred to as...

Descripción completa

Detalles Bibliográficos
Autores principales: Cracco, Laura, Doud, Emma H., Hallinan, Grace I., Garringer, Holly J., Jacobsen, Max H., Richardson, Rose M., Buratti, Emanuele, Vidal, Ruben, Ghetti, Bernardino, Newell, Kathy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452479/
https://www.ncbi.nlm.nih.gov/pubmed/35836354
http://dx.doi.org/10.1111/nan.12836
_version_ 1784784920926748672
author Cracco, Laura
Doud, Emma H.
Hallinan, Grace I.
Garringer, Holly J.
Jacobsen, Max H.
Richardson, Rose M.
Buratti, Emanuele
Vidal, Ruben
Ghetti, Bernardino
Newell, Kathy L.
author_facet Cracco, Laura
Doud, Emma H.
Hallinan, Grace I.
Garringer, Holly J.
Jacobsen, Max H.
Richardson, Rose M.
Buratti, Emanuele
Vidal, Ruben
Ghetti, Bernardino
Newell, Kathy L.
author_sort Cracco, Laura
collection PubMed
description AIMS: Frontotemporal dementias are neuropathologically characterised by frontotemporal lobar degeneration (FTLD). Intraneuronal inclusions of transactive response DNA‐binding protein 43 kDa (TDP‐43) are the defining pathological hallmark of approximately half of the FTLD cases, being referred to as FTLD‐TDP. The classification of FTLD‐TDP into five subtypes (Type A to Type E) is based on pathologic phenotypes; however, the molecular determinants underpinning the phenotypic heterogeneity of FTLD‐TDP are not well known. It is currently undetermined whether TDP‐43 post‐translational modifications (PTMs) may be related to the phenotypic diversity of the FTLDs. Thus, the investigation of FTLD‐TDP Type A and Type B, associated with GRN and C9orf72 mutations, becomes essential. METHODS: Immunohistochemistry was used to identify and map the intraneuronal inclusions. Sarkosyl‐insoluble TDP‐43 was extracted from brains of GRN and C9orf72 mutation carriers post‐mortem and studied by Western blot analysis, immuno‐electron microscopy and mass spectrometry. RESULTS: Filaments of TDP‐43 were present in all FTLD‐TDP preparations. PTM profiling identified multiple phosphorylated, N‐terminal acetylated or otherwise modified residues, several of which have been identified for the first time as related to sarkosyl‐insoluble TDP‐43. Several PTMs were specific for either Type A or Type B, while others were identified in both types. CONCLUSIONS: The current results provide evidence that the intraneuronal inclusions in the two genetic diseases contain TDP‐43 filaments. The discovery of novel, potentially type‐specific TDP‐43 PTMs emphasises the need to determine the mechanisms leading to filament formation and PTMs, and the necessity of exploring the validity and occupancy of PTMs in a prognostic/diagnostic setting.
format Online
Article
Text
id pubmed-9452479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94524792022-10-14 Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72) Cracco, Laura Doud, Emma H. Hallinan, Grace I. Garringer, Holly J. Jacobsen, Max H. Richardson, Rose M. Buratti, Emanuele Vidal, Ruben Ghetti, Bernardino Newell, Kathy L. Neuropathol Appl Neurobiol Original Articles AIMS: Frontotemporal dementias are neuropathologically characterised by frontotemporal lobar degeneration (FTLD). Intraneuronal inclusions of transactive response DNA‐binding protein 43 kDa (TDP‐43) are the defining pathological hallmark of approximately half of the FTLD cases, being referred to as FTLD‐TDP. The classification of FTLD‐TDP into five subtypes (Type A to Type E) is based on pathologic phenotypes; however, the molecular determinants underpinning the phenotypic heterogeneity of FTLD‐TDP are not well known. It is currently undetermined whether TDP‐43 post‐translational modifications (PTMs) may be related to the phenotypic diversity of the FTLDs. Thus, the investigation of FTLD‐TDP Type A and Type B, associated with GRN and C9orf72 mutations, becomes essential. METHODS: Immunohistochemistry was used to identify and map the intraneuronal inclusions. Sarkosyl‐insoluble TDP‐43 was extracted from brains of GRN and C9orf72 mutation carriers post‐mortem and studied by Western blot analysis, immuno‐electron microscopy and mass spectrometry. RESULTS: Filaments of TDP‐43 were present in all FTLD‐TDP preparations. PTM profiling identified multiple phosphorylated, N‐terminal acetylated or otherwise modified residues, several of which have been identified for the first time as related to sarkosyl‐insoluble TDP‐43. Several PTMs were specific for either Type A or Type B, while others were identified in both types. CONCLUSIONS: The current results provide evidence that the intraneuronal inclusions in the two genetic diseases contain TDP‐43 filaments. The discovery of novel, potentially type‐specific TDP‐43 PTMs emphasises the need to determine the mechanisms leading to filament formation and PTMs, and the necessity of exploring the validity and occupancy of PTMs in a prognostic/diagnostic setting. John Wiley and Sons Inc. 2022-07-28 2022-10 /pmc/articles/PMC9452479/ /pubmed/35836354 http://dx.doi.org/10.1111/nan.12836 Text en © 2022 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Cracco, Laura
Doud, Emma H.
Hallinan, Grace I.
Garringer, Holly J.
Jacobsen, Max H.
Richardson, Rose M.
Buratti, Emanuele
Vidal, Ruben
Ghetti, Bernardino
Newell, Kathy L.
Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72)
title Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72)
title_full Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72)
title_fullStr Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72)
title_full_unstemmed Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72)
title_short Distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: FTLD‐TDP Type A (GRN) vs Type B (C9orf72)
title_sort distinguishing post‐translational modifications in dominantly inherited frontotemporal dementias: ftld‐tdp type a (grn) vs type b (c9orf72)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452479/
https://www.ncbi.nlm.nih.gov/pubmed/35836354
http://dx.doi.org/10.1111/nan.12836
work_keys_str_mv AT craccolaura distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT doudemmah distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT hallinangracei distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT garringerhollyj distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT jacobsenmaxh distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT richardsonrosem distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT burattiemanuele distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT vidalruben distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT ghettibernardino distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72
AT newellkathyl distinguishingposttranslationalmodificationsindominantlyinheritedfrontotemporaldementiasftldtdptypeagrnvstypebc9orf72